.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
AstraZeneca
Boehringer Ingelheim
Merck
Novartis
Julphar
Cerilliant
Deloitte
McKesson
McKinsey

Generated: December 18, 2017

DrugPatentWatch Database Preview

Bayer Hlthcare Company Profile

« Back to Dashboard

What is the competitive landscape for BAYER HLTHCARE, and what generic alternatives to BAYER HLTHCARE drugs are available?

BAYER HLTHCARE has fifty-eight approved drugs.

There are fifty-two US patents protecting BAYER HLTHCARE drugs and there have been three Paragraph IV challenges on BAYER HLTHCARE drugs in the past three years.

There are one thousand four hundred and fifty-two patent family members on BAYER HLTHCARE drugs in seventy-three countries and one hundred and thirteen supplementary protection certificates in sixteen countries.

Summary for Bayer Hlthcare

International Patents:1452
US Patents:52
Tradenames:57
Ingredients:38
NDAs:58
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer HlthcareULTRAVIST 240iopromideINJECTABLE;INJECTION020220-003May 10, 1995RXYesYes► Subscribe► Subscribe► Subscribe
Bayer HlthcareBEYAZdrospirenone; ethinyl estradiol; levomefolate calciumTABLET;ORAL022532-001Sep 24, 2010ABRXNoNo► Subscribe► SubscribeY► Subscribe
Bayer HlthcareTRASYLOLaprotininINJECTABLE;INJECTION020304-001Dec 29, 1993DISCNNoNo► Subscribe► Subscribe► Subscribe
Bayer HlthcareCIPROciprofloxacin hydrochlorideTABLET;ORAL019537-003Oct 22, 1987ABRXYesYes► Subscribe► Subscribe► Subscribe
Bayer HlthcareNEXAVARsorafenib tosylateTABLET;ORAL021923-001Dec 20, 2005RXYesYes► Subscribe► Subscribe► Subscribe
Bayer HlthcareMENOSTARestradiolFILM, EXTENDED RELEASE;TRANSDERMAL021674-001Jun 8, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Bayer HlthcareADEMPASriociguatTABLET;ORAL204819-002Oct 8, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Bayer HlthcareNEXAVARsorafenib tosylateTABLET;ORAL021923-001Dec 20, 2005RXYesYes► Subscribe► SubscribeY► Subscribe
Bayer HlthcareCIPROciprofloxacinFOR SUSPENSION;ORAL020780-002Sep 26, 1997ABRXYesYes► Subscribe► Subscribe► Subscribe
Bayer HlthcareEOVISTgadoxetate disodiumSOLUTION;INTRAVENOUS022090-001Jul 3, 2008RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bayer Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer HlthcareMYCELEXclotrimazoleTROCHE/LOZENGE;ORAL018713-001Jun 17, 1983► Subscribe► Subscribe
Bayer HlthcareMYCELEXclotrimazoleSOLUTION;TOPICAL018181-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Bayer HlthcareULTRAVIST 150iopromideINJECTABLE;INJECTION020220-004May 10, 1995► Subscribe► Subscribe
Bayer HlthcareCIPROciprofloxacinINJECTABLE;INJECTION019847-001Dec 26, 1990► Subscribe► Subscribe
Bayer HlthcareBEYAZdrospirenone; ethinyl estradiol; levomefolate calciumTABLET;ORAL022532-001Sep 24, 2010► Subscribe► Subscribe
Bayer HlthcareULTRAVIST (PHARMACY BULK)iopromideINJECTABLE;INJECTION021425-002Sep 20, 2002► Subscribe► Subscribe
Bayer HlthcareULTRAVIST 240iopromideINJECTABLE;INJECTION020220-003May 10, 1995► Subscribe► Subscribe
Bayer HlthcareCLIMARA PROestradiol; levonorgestrelFILM, EXTENDED RELEASE;TRANSDERMAL021258-001Nov 21, 2003► Subscribe► Subscribe
Bayer HlthcareBEYAZdrospirenone; ethinyl estradiol; levomefolate calciumTABLET;ORAL022532-001Sep 24, 2010► Subscribe► Subscribe
Bayer HlthcareCIPROciprofloxacinFOR SUSPENSION;ORAL020780-001Sep 26, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BAYER HLTHCARE drugs

Drugname Dosage Strength Tradename Submissiondate
azelaic acidTopical Foam15%FINACEA9/14/2017
regorafenibTablets40 mgSTIVARGA9/27/2016
drospirenone and estradiolTablets0.25 mg/0.5 mgANGELIQ1/8/2015
sorafenib tosylateTablets200 mgNEXAVAR2/28/2014
moxifloxacin hydrochlorideInjection1.6 mg/mLAVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER2/7/2014
drospirenone and ethinyl estradiol and levomefolate calcium and levomefolate calciumTablets3 mg/0.02 mg/0.451 mg and 0.451 mgBEYAZ11/13/2012
drospirenone and ethinyl estradiol and levomefolate calcium and levomefolate calciumTablets3 mg/0.03 mg/0.451 mg and 0.451 mgSAFYRAL9/28/2012
azelaic acidGel15%FINACEA7/27/2012
vardenafil hydrochlorideOrally Disintegrating Tablets10 mgSTAXYN12/22/2011
drospirenone and ethinyl estradiol and levomefolateTablets3 mg/0.02 mg/0.451 mg and 0.451 mgBEYAZ11/21/2011
desonideGel0.05%DESONATE12/1/2010
estradiol valerate and dienogestTablets3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mgNATAZIA10/22/2010
ciprofloxacinOral Suspension250 mg/5 mL and 500 mg/ 5 mLCIPRO10/16/2009
vardenafil hydrochlorideTablets2.5 mgLEVITRA9/4/2009
vardenafilTablets5 mg ad 10 mgLEVITRA7/10/2009
vardenafil hydrochlorideTablets20 mgLEVITRA3/5/2009
drospirenone and estradiolTablets0.5 mg/1 mgANGELIQ12/26/2007
drospirenone and ethinyl estradiolTablets3 mg/0.02 mgYAZ9/29/2006
estradiolTransdermal System0.05 mg/day and 0.1 mg/dayCLIMARA9/12/2005
acarboseTablets25 mg, 50 mg and 100 mgPRECOSE3/22/2005
drospirenone and ethinyl estradiolTablets3 mg/0.03 mgYASMIN1/7/2005

Premature patent expirations for BAYER HLTHCARE

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe
► Subscribe ► Subscribe
► Subscribe ► Subscribe

Non-Orange Book Patents for Bayer Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,539,208Foam prepared from nanoemulsions and uses► Subscribe
9,492,412Penetrating pharmaceutical foam► Subscribe
9,622,947Foamable composition combining a polar solvent and a hydrophobic carrier► Subscribe
9,713,643Foamable carriers► Subscribe
6,517,847 Topical gel delivery system► Subscribe
8,242,147Aryl ureas with angiogenisis inhibiting activity► Subscribe
8,486,374Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses► Subscribe
9,452,082Inserter► Subscribe
9,636,405Foamable vehicle and pharmaceutical compositions thereof► Subscribe
8,741,265Penetrating pharmaceutical foam► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bayer Hlthcare Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)0040275► Subscribe
Japan5215666► Subscribe
Poland340631► Subscribe
Portugal918791► Subscribe
Poland194020► Subscribe
Germany19654609► Subscribe
Austria497387► Subscribe
Denmark1598069► Subscribe
South Africa200103141► Subscribe
Norway965298► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bayer Hlthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014 00027Denmark► SubscribePRODUCT NAME: RADIUM-223 OG OPLOESELIGE SALTE DERAF, HERUNDER RADIUM-223 DICHLORID; REG. NO/DATE: EU/1/13/873 20131113
1214076/01Switzerland► SubscribePRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
0814Netherlands► SubscribePRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
C/GB05/021United Kingdom► SubscribePRODUCT NAME: GADOXETIC ACID, OPTIONALLY IN THE FORM OF A SALT; REGISTERED: SE 18929 20040326; SE 18930 20040326; UK PL 00053/0348 20041110; UK PL 00053/0349 20041110
643Luxembourg► Subscribe91643, EXPIRES: 20211022
4Finland► Subscribe
90030-2Sweden► SubscribePRODUCT NAME: RIOCIGUAT OCH SALTER, ISOMERER OCH HYDRATER DAERAV; REG. NO/DATE: EU/1/13/907 20140327
7Finland► Subscribe
2006009Lithuania► SubscribePRODUCT NAME: DROSPIRENONUM; NAT. REGISTRATION NO/DATE: LT/1/06/0520/001, 2006 07 10 LT/1/06/0520/002, 2006 07 10 LT/1/06/0520/003, 2006 07 10 LT/1/06/0520/004 20060710; FIRST REGISTRATION: RVG 31781 20050804
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
AstraZeneca
Chinese Patent Office
Express Scripts
Chubb
Julphar
Mallinckrodt
Teva
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot